Thrilled to announce that our SNIP paper is live @CellCellPress! SNIP is a high-performance drug-regulated CAR platform that is optimized for the clinic--plans for a trial are already underway @StanfordMed. #CART #Immunotherapy #SynBio #Cancer. sciencedirect.com/science/ar… 1/

Today we’re sharing an update on Claude’s protein design capabilities. Working with Adaptyv Bio and Twist Bioscience, Claude designed de novo protein binders against 14 of 15 targets. With a 30k token prompt written by a human expert, Claude achieved hit rates up to 28.2% when designing against all targets simultaneously over 48 hours, with no human intervention or steering. When designing against a single target in a 24 hour campaign, Claude achieved an overall hit rate of 35%. We included all targets in Adaptyv’s BenchBB, and novel targets 15-PGDH and GDF-8. Claude performs at or beyond the level of the top competition participants in both hit rate and binding affinity.

Very pleased to share this new commentary on the extraordinary biology of resident tissue macrophages (RTMs). RTMs are the most evolutionarily conserved immune cells. They emerged before adaptive immunity and blood circualtion (1/4) rdcu.be/fusPs

Excited to share our new study @ScienceMagazine by the fantastic Raphael Mattiuz and @jboumelha @SinaiImmunol showing how DC build and sustain tertiary lymphoid structures in cancer. A major step toward enhancing anti-tumor immunity (1/2) science.org/doi/10.1126/scie…

Congratulations to @jeremiahfaith1, @grinsa01, and @sinaiimmunology on a big milestone in microbiome therapeutics: nature.com/articles/s41591-0… (1/2)

Today in @NatureBiotech we report a new suit of PE8 prime editor proteins. PE8 variants were developed from laboratory-evolved PE6 proteins using AI-guided protein redesign. This approach combines recent advances in computational protein design and directed evolution to increase prime editing efficiency, especially in transient therapeutically relevant delivery settings such as mRNA+pegRNA electroporation into primary cells, eVLP delivery of prime editing RNPs, and LNP-mediated mRNA+pegRNA delivery in mice. drive.google.com/file/d/13VT… 1/11

The proposed FY2027 budget includes a $5.8B (−12.3%) cut to the NIH. United for Medical Research calculated this could cost ~50,000 jobs and $11.6B in economic activity, with 26 states losing >$100M each. A tragedy for science, patients, and the economy. #NIH

We're pleased to share this review on current & future macrophage-targeted therapies as a central pillar of next-generation immunotherapy. Written with the fantastic @MatthewD_Park, Brian Brown & Kevin Sun. doi.org/10.1016/j.ccell.2026…

Thrilled to share our first iteration of IL-12–armored CAR T cells targeting tumor associated macrophages (TAM) to treat metastatic cancer. Led by the fantastic @jaimemateustique as a collaboration between @brown_lab1 and my lab @sinaiimmunology. authors.elsevier.com/a/1mUUD… (1/4)

Powerful, bipartisan concern about NIH cuts at today’s Congressional hearing, with thoughtful questions from both sides of the aisle. Thank you @SenCapito, @SenatorBaldwin & @SenatorCollins for standing up for science. piped.video/live/pNSYfQYuxqk… via @YouTube

RT @PearlF: As the US Congress is considering a bill to sabotage US economic growth with a 40% slash to the NIH budget (world's largest inn…

Excited to see our research led with phenomenal @MatthewD_Park & Tom Marron in @WSJ ! this builds on years studying inflammation in cancer, now redirected to aging. Now we're launching trials to test if modulating inflammation can prevent age-related diseases.@SinaiImmunol

Powerful piece on the dominance of NIH-funded science and its role in drug discovery. Cutting the NIH budget puts all the U.S. has built at risk. We urge @RFKJr_Official & @NIHDirector_Jay to champion U.S. science and defend NIH funding statnews.com/2025/06/06/us-u… via @statnews

🚨 New Preprint 🚨 A continuous landscape of signaling encodes a corresponding landscape of CAR T cell phenotype How can we tune JAK/STAT signaling to create better immune cell therapies? doi.org/10.1101/2025.06.05.6…

.@SecKennedy - thank you so much for your broad support for gene editing and gene therapies as well as recognizing the importance of Baby KJ’s story and the potential that CRISPR base editing therapies hold for patients with severe genetic diseases. I’m thrilled you have publicly recognized the Herculean efforts that made KJs therapy possible, from the physicians @CHOP like @kiranmusunuru and Rebecca Ahrens-Nicklas to the technological innovation in @davidrliu and @BKleinstiver labs, and especially the coordination and cooperation of the regulators @US_FDA that made this possible. The gene editing medicine KJ received, a CRISPR adenine base editor was invented and developed in @davidrliu lab @Harvard with government grants from the NIH. This life-saving medicine, and so many future technologies, could not and will not be possible without government grants such as the one that supported this work, but are now shut off by this administration. So PLEASE ask this administration to stop attacking our academic institutions and restore government funding to @Harvard (where again, KJ’s medicine was created!!) We cannot have stories like KJ’s without full and unwavering support from the US government. Please help, please.

.@SecKennedy said yesterday at the FDA: "CRISPR gives the gift of life." He is 100% correct. I appreciate HHS, FDA, CMS, NIH, and CBER leadership devoting their morning to communicate their clear support for CRISPR giving such a gift to all of our nation's children who need it.

Thursday morning, I had the privilege of speaking with the Muldoon family, whose 10-month-old son, baby KJ, was discharged Wednesday from @ChildrensPhila. Baby KJ was diagnosed with a rare urea cycle disorder and received a first-of-its-kind personalized CRISPR gene-editing therapy—customized specifically for his unique mutation. Thanks to the extraordinary expertise and compassion of the team at CHOP and the researchers who developed this pioneering treatment, baby KJ now has a second chance at life. The Muldoon family’s courage is nothing short of inspiring, and I offer my deepest gratitude to everyone at CHOP and beyond who made this medical milestone possible. This isn’t just a medical success story—it’s a powerful glimpse into the future of personalized medicine. I remain firmly committed to working with @NIHDirector_Jay, @DrMakaryFDA, @DrOzCMS, and others to ensure that: • HHS continues to invest in cutting-edge research that drives breakthrough therapies • Our regulatory frameworks keep pace with rapid innovation • No family is ever denied access to life-saving treatments because of cost Breakthroughs like this are why we do the work.

LIVE NOW: FDA's Cell and Gene Therapy Roundtable Captions available here: bit.ly/4dQaNaz nitter.siddz.com/i/broadcasts/1ypKdZYAp…

Please check out our paper published today in Nature that identifies CREM as a key checkpoint limiting CAR NK cell function.CRISPR knockout of CREM significantly enhanced anti-tumor activity, implicating a broader role in NK cell regulation. Huge congrats to @hindrafei and our

🧵1/ T cells have deservedly been in the🔦for #cancer #immunotherapy, but other engineered cell therapies are now📈. What mediates NK cell exhaustion remains an important unanswered❓. 📄Link: nature.com/articles/s41586-0… I’m so thrilled🥳to share our work out now🚨@Nature identifying🔎CREM as a central intracellular checkpoint🚦in #CARNK cells. Let me tell you a story...👇🏼

Cancer survivor warns against threats to health funding Watch the full video here: tinyurl.com/3hmsesae